Polycystic Ovary Syndrome Syndrome Research Articles

Metabolic Consequences of Polycystic Ovary Syndrome on Hepatic Function in High Fat Diet-Fed Rats: Potential Role of Exercise

Abstract Context Polycystic ovarian syndrome (PCOS) is the most common endocrine-metabolic disorder in reproductive-aged women. Since, The current study was designed to elucidate the metabolic comorbidities of polycystic ovarian syndrome, especially the hepatic effect, with or without high fat diet feeding, and to emphases the crucial role of exercise in managing such complications. Materials and Methods This study was carried out on 55 adult female albino Wistar rats, the study duration was 8 weeks. Rats included in the present study were randomly allocated into five equal groups, eleven rats each: Group I: Control group, Group II: Polycystic ovary syndrome (PCO) group, Group III: High fat diet fed polycystic ovary syndrome (HF-PCO) group, Group IV: Exercise-treated polycystic ovary syndrome (PCO-EX) group, Group V: High fat diet fed exercise-treated polycystic ovary syndrome (HF-PCO-EX) group. PCOS was induced in female wistar rats by oral administration of Letrozole (1mg/kg daily by oral gavage for 21 days in groups II, III, IV, V, high fat diet was supplemented to groups III and V. Rats of groups IV and V were subjected to 30 minutes swimming protocol 5 days/ week for 5 weeks after the period of induction. Results All measured values of the OGTT as well as area under the curve, serum fasting glucose (FG), insulin levels and HOMA-IR were all significantly increased in the PCO, HF-PCO when compared to control group. Compared to their corresponding non exercised groups, both PCO-EX and HFPCO-EX groups showed significant reductions in all parameters except for T90 in PCO-EX group. For the lipid profile, the serum level of TG, TC, LDL-C and AI were all significantly increased while HDL-C was significantly decreased in PCO and HF-PCO compared to control group as well as in HF-PCO group compared to PCO group. PCO-EX and HF-PCO-EX groups showed significant reductions in TG, TC, LDL-C and AI and a significant elevation in HDL-C when compared to their corresponding non- exercised groups. For liver enzymes serum level of ALT, AST and GGT were significantly increased in PCO and HF-PCO groups when compared with control group. Compared to their corresponding non exercised groups, both PCO-EX and HF-PCO-EX showed significant reductions in liver enzymes. As regard the hormonal profile, the serum level of estradiol, adiponectin and adiponectin/resistin ratio (A/R) were significantly decreased while serum level of testosterone, LH and resistin were significantly increased in PCO and HF-PCO groups compared to control group. PCO-EX and HF-PCO-EX groups induced significant increases in serum estradiol, adiponectin and A/R as well as significant decreases in serum testosterone, LH and resistin compared to their corresponding non exercised groups. Conclusion We could conclude that both moderate intensity exercise and avoiding high fat diet have beneficial therapeutic potentials in ameliorating the metabolic effects of PCO syndrome in rats especially the hepatic effects and the development of NAFLD.

The significant improvement in ovarian PCOS syndrome using hydralazine and alendronate aromatase inhibitor FDA-approved drugs in Wistar rat models

Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility. The aim of this study was to investigate the therapeutic potential of vitamin C, glutamine, mesalazine, hydralazine, and alendronate as new drug candidates for the treatment of letrozole-induced PCOS in female Wistar rats. PCOS was induced in rats by intramuscular injection of estradiol valerate (2 mg/kg body weight for 28 days). The rats then received normal saline (PCOS group), letrozole (0.5 mg/kg), vitamin C (100 mg/kg), glutamine (1000 mg/kg), mesalazine (200 mg/kg), hydralazine (30 mg/kg), and alendronate (17.5 mg/kg). Serum testosterone, LH, FSH, estradiol and progesterone levels were determined by ELISA method. H&E staining was used for histological analysis in the ovarian tissues. The groups treated with hydralazine and alendronate, show a significant decrease in testosterone, LH hormone, cystic and atretic follicles, and a significant increase in the number of single layer, multilayer, antral, graafian follicles and the volume of corpus luteum as compared to the PCOS group. Hydrolazine and alendronate appear to be effective in restoring folliculogenesis and increasing ovulation in PCOS rat. So that the natural process of ovulation and the improvement of the histology of polycystic ovaries and its shift towards healthy and active ovaries were observed. This finding supports the potential beneficial effect of hydrolazine and alendronate on improving PCOS complication.

Elevated Insulin-Like Growth Factor-1-Induced Female Rats Perpetuate the Polycystic Ovary Syndrome Phenotype: Pathological Mechanism of Insulin-Like Growth Factor-1 in Polycystic Ovary Syndrome

Objectives: This study was designated to establish a polycystic ovary syndrome (PCOS) rat model with recombinant human insulin-like growth factor-1 (RH-IGF-1). We made assessment on the characteristics of hyperinsulinemia and hyperandrogenism in the rat model. Design: This study performed the characteristics of PCOS upon RH-IGF-1 injection and evaluated the disease process of PCOS syndrome caused by the insulin-resistant pathological condition of IGF-1 based on the comparative study of in vivo test. Setting: The experiment was conducted in the experimental research center of Yinzhou NO.2 hospital, Ningbo, Zhejiang Province, China. Materials and Methods: Thirty-four female Sprague Dawley immature rats aged 21 days were randomly divided into two groups. Those treated with RH-IGF-1 2 mg/100 g daily were in RH-IGF-1 group (n = 20), and those with 0.9% sodium chloride 0.2 mL/100 g daily were in the saline group (n = 14). The experiment was carried out in two stages. In stage I, rats were anesthetized upon the first estrous cycle in the saline group with tissue and blood samples collected (n = 7), and rats in the RH-IGF-1-treated group were anesthetized on the 5th day after vaginal opening (VO) (n = 10). In stage II, rats in the saline group were anesthetized after three complete cycles (n = 7), meanwhile, while on the 15th day after VO (n = 10) for those in the RH-IGF-1 group. Results: We have found that compared with the control group, rats injected with RH-IGF-1 expressed an early VO, disordered estrous cycle, polycystic ovaries, and significantly increased ovarian weight/body weight ratio. And from the perspective of hormone secretion, their androgen increased significantly and the insulin resistance index also elevated distinctly, possessing main characteristics similar to PCOS. Limitations: In this study, we were limited by the inability to examine IGF-1 in hypothalamus. IGF-1 in hypothalamus and in vitro experiments would be taken into consideration for further study in the future. Conclusions: These findings suggest that IGF-1 may be a key factor in the pathogenesis of PCOS, and the increase of androgen may be the pathological result, not the cause of PCOS.

AGE-RELATED CHANGES OF HORMONAL HOMEOSTASIS IN POLYCYSTOSIS OF OVARIANS

Violation of hormonal homeostasis in polycystic ovary syndrome (PCOS) causes a number of changes in the body of a woman in the postmenopausal period. One of the clinical features of the climacteric syndrome in PCOS is the presence of rare and weak hot flashes, a decrease in the menopausal peak of gonadotropins, and a distinct appearance of local urogenital symptoms. With age, in women with PCOS, a history of insulin resistance and dyslipidaemia predisposes them to early onset of cardiovascular disease and type 2 diabetes. Pathogenetic treatment of women with a history of PCOS in the postmenopausal period should be carried out in order to prevent atherosclerotic and metabolic complications. Keywords: postmenopause, polycystic ovary syndrome, insulin resistance

Waist circumference and waist-to-hip ratio as indicators of abdominal obesity

Obesity is linked to various gynaecological conditions like polycystic ovary syndrome (PCOS) and leads to metabolic syndrome. Early diagnosis of visceral obesity would help control the occurrence and progression of these diseases The aim of the study was to compare waist circumference and waist-to-hip ratio with body mass index (BMI) as indicators of abdominal obesity. This cross-sectional study was conducted on 44 women with Polycystic ovary syndrome (PCOS) fulfilling Rotterdam criteria over a period of one year. Height, weight, waist circumference and hip circumference were measured. BMI and waist to hip ratio were calculated. These were compared with each other. Overall, average waist circumference and waist to hip ratio were found to be 68. 69 cm and 0. 82 respectively and mean BMI was 23. 07 kg/m2. The prevalence of obesity by BMI was 69%, abdominal obesity for WC was 59. 1% while for WHR 61. 36 %. Waist circumference was found to have high positive correlation with BMI (r=0. 75) compared to waist to hip ratio (r=0. 40). Thus, waist circumference and waist hip ratio are easy methods of measuring fat distribution and can be used for the monitoring the development of metabolic syndrome in PCOS.

Quantitative Changes in White Blood Cells: Correlation with the Hallmarks of Polycystic Ovary Syndrome.

Background and Objectives: In women of reproductive age, leukocytosis is a risk factor that bridges low-grade chronic inflammation (metabolic inflammation), metabolic changes, and polycystic ovary syndrome (PCOS) and is a potential early predictor of PCOS. This study aims to explore the predictive role of quantitative changes in white blood cells (WBCs) and neutrophils in PCOS-associated metabolic changes. Materials and Methods: A total number of 176 blood samples were obtained from age-matched women of the reproductive period, comprising 88 PCOS cases and 88 healthy controls. Hematological, metabolic, and anthropometric indices and ultrasonic assessment were recorded. Results: Elevated levels of luteinizing hormone, testosterone, and lipid parameters except HDL-C levels, and the prevalence of metabolic syndrome in PCOS were statistically significant (p < 0.001). The neutrophil count and neutrophil–lymphocyte ratio (NLR) in PCOS patients were significantly higher (p < 0.001) than their counterparts. The predictive ability of the neutrophil count and neutrophil–lymphocyte ratio (NLR) for PCOS, and possibly its associating subclinical inflammation at optimum cut-off values for the neutrophil count and NLR of >46.62% (sensitivity 94.32% and specificity 74.42%) and >1.23 (sensitivity 71.59% and specificity 100%), respectively. With regard to the areas under the curve (AUC) and Youden indices, they constituted 0.922 and 0.697 for neutrophil count and 0.926 and 0.716 for NLR, respectively. The comparative ROC z-statistic value was 2.222 and a p = 0.026. The multiple linear regression analysis revealed no significant influence for hormonal and metabolic independent variables on the neutrophil count in PCOS cases, but, as can be expected, revealed a significant negative relationship with the other components of WBCs. Conclusion: In conclusion, relative neutrophilia and elevated NLR are potential cost-effective, sensitive, and specific predictors of PCOS that may also shed light on the mechanism of chronic low-grade inflammation that is characteristic of the disease.

Extraction and Identification of Active Components from Herbs for their Application for Prevention of Poly Cystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disorder that causes reproductive and metabolic disturbances. PCOS is more common in females who have obesity and it can also be a genetic disorder in some females. During a study on teen age 17-19 years aged girls in Thailand, the prevalence rate of PCOS syndrome was 5.29 %. While, the studies in Iran had shown the prevalence rate to be 8.3% to 11.4% (Naz et al, 2019). PCOS can be treated by allopathic medicines but they have number of side effects in women like acne and menstrual irregularity. Therefore, in this study an alternative solution has been taken to prevent PCOS by the application of herbs. In this study, 7 samples of herbs were considered. Sample of Cinnamon (dalchini) was collected from a field of Punjab Agriculture University Ludhiana; Curcuma longa (turmeric), Mentha piperita (pippermint) and Allium sativum (garlic) were taken from Gurudwara Bhora Sahib (Jagraon); Ocimum sanctum (tulsi), Azadirachta indica (neem) and Casearia esculanta (saptrangi) were collected from Farm house of CT university campus (Mullanpur). These samples were dried for 48 hours at temperature 38˚C. The process of solvent extraction was used to extract the active components. To identify the extracted constituents from herbs, thin layer chromatography (TLC) was done. Some biochemical tests were performed, to confirm the presence of the identified components. From these 7 samples the active components that were successfully identified were cinnamaldehyde, allicin, estradiol and diterpenoids, alkaloids and flavonoids. These components will be further used for the preparation of herbal medicine against

Amino acid signatures in relation to polycystic ovary syndrome and increased risk of different metabolic disturbances

Research questionDo women with polycystic ovary syndrome (PCOS) have a distinct plasma amino acid profile and do potential amino acid markers exist for different metabolic risks of PCOS? DesignChinese Han women (n = 380; 190 with PCOS and 190 controls matched for age and BMI) were recruited and basal state plasma collected. The concentrations of 50 amino acids were quantitatively determined by high-performance LCMS. ResultsThirty-one amino acids had abnormal levels in the PCOS group versus the control group. Twenty-eight amino acids were upregulated and three amino acids downregulated. Multivariate statistical analysis identified 13 amino acids as potential metabolic markers of PCOS; of these, ROC curve analysis revealed 10 amino acids with high sensitivity and specificity for diagnosing PCOS (AUC >0.80). The combination of these 10 amino acids were better able to diagnose PCOS than clinical endocrine parameters. Specific amino acids were associated with increased odds of obesity, insulin resistance and metabolic syndrome in PCOS. Alterations of tyrosine, lysine, methionine, hydroxyarginine, 3-methyhistidine, GABA, methylhistidine and glycine were related to obesity in women with PCOS; enhanced levels of branched-chain amino acids, tyrosine, alanine and lysine were correlated to insulin resistance in the PCOS group; a combination of alanine, valine, leucine, tyrosine, glutamic acid, cysteine and glycine indicated the predictive potential of metabolic syndrome risk in women with PCOS. ConclusionsWomen with PCOS suffered from severe dysfunction of amino acid metabolism. Specific amino acid signatures could be used as powerful markers for diagnosing PCOS and predicting metabolic disturbances.

Conservative possibilities influencing PCOS syndrome - the importance of nutrition.

Polycystic ovary syndrome (PCOS) is a common pathological condition in women. Conservative treatment is used in the treatment of polycystic ovary syndrome. Conservative treatment options include increased physical activity and diet. The main aim of the article is to discuss the therapeutic treatment of influencing PCOS from a nutritional point of view. PCOS is associated with several comorbidities, including infertility, metabolic syndrome, obesity, impaired glucose tolerance, diabetes mellitus II, and increased cardiovascular risk. Several therapeutic diets can be used in the treatment of PCOS, such as the DASH diet, the low-carbohydrate diet, and a diet based on a low glycemic index. A change in eating habits is associated with improvement in PCOS symptoms.

Особенности лечения пациенток с синдромом поликистозных яичников и метаболическим синдромом

This paper discusses polycystic ovary syndrome (PCOS), a common endocrine disorder characterized by hirsutism, anovulation, and polycystic ovaries. Insulin resistance which is considered the major causative factor for both PCOS and metabolic syndrome is emphasized. The early diagnosis of metabolic disorders which increase the risk of cardiovascular complications and the complications of pregnancy (including gestational diabetes and hypertension which may result in preeclampsia and placental abruption) is of particular importance. The presence of metabolic syndrome in PCOS is associated with poor prognosis in terms of fertility and has a negative impact on the outcomes of in vitro fertilization in infertile women with PCOS. When describing treatment approaches, the role of metformin, inositol, folates, vitamin D, and statins in treating metabolic disorders in PCOS and metabolic syndrome, reducing the risks of cardiovascular complications, and realizing fertile function is highlighted. The course of PCOS is complicated by psychic disorders (i.e., depression, anxiety, bipolar disorder, or eating disorders) which are common in these women and should be considered when prescribing medications. KEYWORDS: polycystic ovary syndrome, insulin resistance, infertility, metabolic syndrome, cardiovascular complications, inositol, folates. FOR CITATION: Il’ina I.Yu. Specificities of the treatment for polycystic ovary syndrome and metabolic syndrome. Russian Journal of Woman and Child Health. 2020;3(4):254–259. DOI: 10.32364/2618-8430-2020-3-4-254-259.

Long non-coding RNA steroid receptor activator in polycystic ovary syndrome: possible association with metabolic syndrome

Introduction: Polycystic ovary syndrome (PCOS) is a metabolic and endocrine disorder which affects women of reproductive age with a prevalence of 8-18% and implies various severe consequences to female health, including alarming rates of infertility, which accounts for approximately 75% of anovulatory infertility. Long non-coding RNA steroid receptor activator (lncRNA-SRA) affects multiple biological processes. However, it is not known whether lncRNA-SRA is associated with PCOS and the possible accompanied metabolic syndrome (MetS). Material and Methods: The expression levels of lncRNA-SRA were measured by real-time quantitative-PCR in PCOS patients (n=30 women), and in control group (n=20 women), patients with metabolic syndrome were diagnosed, and the association between lncRNA-SRA and metabolic syndrome parameters in PCOS group and control were analyzed. Results: LncRNA-SRA expression mean level was significantly higher in the women with PCOS than that in the control group. There was a high significant positive correlation between lncRNA-SRA expression and hirsutism, BMI, waist circumference (WC), and insulin levels, also with significant positive correlation between lncRNA-SRA with HOMA/IR and testosterone in PCOS group. Conclusion: The authors found that the lncRNA-SRA expression is potentially increased with PCOS and it has positive correlation with hirsutism, obesity, testosterone, and insulin resistance in PCOS. LncRNA-SRA is significantly increased in MetS subgroup of PCOS, thereby suggesting that elevated lncRNA-SRA might be an important mediator not only associated to hormonal and clinical parameters but also associates metabolic syndrome in PCOS and may be a mediator in the pathogenesis of both syndromes.

Incidence of metabolic syndrome in polycystic ovarian syndrome in Iranian women

Introduction: Polycystic ovary syndrome (PCOS) is the most common cause of the chronic anovulation including 5-10% of women in reproductive ages. The association between increased insulin resistance and polycystic ovaries is now well-recognized. This clinical association of hyperinsulinemia and anovulatory hyperandrogenism is commonly found throughout the world. Insulin resistance is only one component of a condition which is now called metabolic syndrome. In different studies, the prevalence of this syndrome outbreak is reported 7-43% .This study was performed to determine the prevalence and predictors of the metabolic syndrome in PCOS in southwest of Iran. Materials and Methods: The study included 53 women were diagnosed with PCOS, according to the Rotterdam criteria. Metabolic syndrome was assessed according to the criteria of the American National Cholesterol Panel (ATP-III criteria). The prevalence of metabolic syndrome was studied through measuring the following items: fasting glucose, triglyceride, HDL cholesterol, blood pressure, weight, height and waist circumference. We considered the patients as a metabolic syndrome group who has 3 or more cases. Results: Based on this research, the prevalence of metabolic syndrome in Ahwaz women was estimated 13.5%, the prevalence for individual components comprising the metabolic syndrome were: fasting glucose concentrations greater than or equals to 110 mg/dl in 4 patient(7.7%), hypertension in 4 patients (7.7%), BMI higher or equals to 30 in 6 patients (11.5%), waist circumference greater than or equals to 88 cm in 14 patients (34.1%), HDL less than 40 mg/dl in 12 patients (24%), triglyceride greater than or equals to 150 mg/dl in 5 patients(9.4%), IFG in 17 patients (32.7%), diabetes in 3 patients (5.8%) and dislipidemia in 31 patients(60%). Conclusions: Our results show the metabolic syndrome and its elements occur frequently in women with PCOS, particularly those with the classic picture of the syndrome. The latter combination places them at risk for cardiovascular diseases and screening for those disturbances is required in patients with PCOS.

Managing polycystic ovary syndrome in primary care.

Polycystic ovary syndrome (PCOS) presents with a spectrum of conditions resulting from androgen excess, anovulation and metabolic syndrome. Patients with PCOS may see their primary care physicians for various presentations, including hirsutism, acne, menstrual irregularities, infertility, obesity, and psychiatric disorders such as anxiety and depression. Management of these patients should include screening for Type 2 diabetes mellitus, dyslipidaemia and hypertension. Treatment should be targeted to each patient's phenotype and personal expectations such as desire for pregnancy. Psychological well-being due to the effects on physical appearance is also an important consideration. Diet and exercise are major components in the management of patients with PCOS and obesity. The first-line therapy for fertility and metabolic syndrome in PCOS is lifestyle modification with diet and exercise, followed by pharmacological therapy.

Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression.

Women with polycystic ovary syndrome (PCOS) have increased risk of metabolic syndrome. The relative contribution of clinical, demographic or biochemical factors to metabolic syndrome in PCOS is not known. A literature search was conducted in MEDLINE, CINAHL, EMBASE and clinical trial registries. Of 4530 studies reviewed, 59 were included in the systematic review and 27 in the meta-analysis and meta-regression. In good and fair quality studies, women with PCOS had an overall increased prevalence of metabolic syndrome (odds ratio, OR 3.35, 95% confidence interval, CI 2.44, 4.59). Increased prevalence of metabolic syndrome occurred in overweight or obese women with PCOS (OR 1.88, 95% 1.16, 3.04) but not in lean women (OR 1.45, 95% CI 0.35, 6.12). In meta-regression analyses, the markers of metabolic syndrome diagnostic criteria (waist circumference, high-density lipoprotein cholesterol, triglyceride, blood pressure), BMI, glucose tolerance (2-hr oral glucose tolerance test) and surrogate markers of insulin resistance (HOMA-IR) but not markers of reproductive dysfunction (sex hormone binding globulin, testosterone, PCOS phenotypes) contributed significantly to the heterogeneity in the prevalence of metabolic syndrome. Women with PCOS have increased risk of metabolic syndrome which was associated with obesity and metabolic features but not with indices of hyperandrogenism.

New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome.

Polycystic ovary syndrome (PCOS) is a pathophysiological disorder affecting reproductive and metabolic indices. PCOS is commonly associated with a high prevalence of insulin resistance and obesity; this association carries an increased risk of developing metabolic syndrome, type 2 diabetes mellitus (T2DM), and cardiovascular disease. Guidelines recommend lifestyle modification, metformin, hormonal contraceptives (HCs), and bariatric surgery as the main treatment options in obese patients with PCOS. Studies are being conducted to test the efficacy of existing treatment options as well as to discover new therapies. This review focuses on the most recent advances in this regard and highlights new hypotheses and emerging studies to give a picture of the latest therapeutic trends in the treatment of obese patients with PCOS. In this respect, much attention is given to the role of inositols, the mediators of insulin action. A deficiency of d-chiro-inositol containing inositol-phospho-glycans may be the basis of insulin resistance frequently seen in PCOS patients. Moreover, evidence suggests the use of statins in obese women with PCOS, but guidelines call for further research. Adiponectin, quercetin, vitamin D, and anti-obesity drugs have also been studied and seem to have a useful role in the treatment of obesity and metabolic syndrome in PCOS. Many trials have been conducted on the use of non-pharmacological therapies. Therapies including resveratrol, acupuncture, and berberine have favorable effects in overweight PCOS patients. However, more research is needed to reveal the clinical complexity of PCOS and develop more effective treatment options.

Studying the Frequency of Helicobacter Pylori Infection Among Women Suffering from Polycystic Ovary Resorting to Hospital Infertility Center

Introduction Polycystic ovary syndrome (PCOS) is one of the most common complication of internal glands among patients before menopause. A frequency of 4 to 12 percent is reported for this syndrome (1). PCOS syndrome was first introduced in 2016 (2). The most common symptoms of this syndrome are

Comparison of Metformin and Simvastatin Administration in Women With Polycystic Ovary Syndrome Before Intra-Cytoplasmic Sperm Injection Cycle: A Prospective, Randomized, Clinical Trial Study.

Background:Drugs administration as a pretreatment regiment before ICSI cycle in PCOs patients could enhance the success rate.Objectives:The aim of this study was to compare the effectiveness of metformin with Simvastatin in patients with polycystic ovary syndrome (PCOs) candidates for intra-cytoplasmic sperm injection (ICSI) before starting the cycle.Patients and Methods:In this prospective, double blind, randomized clinical trial the efficacy of these drugs was evaluated in 40 women with PCO syndrome (20 patients in each group; A: simvastatin and B: metformin) candidates for ICSI. In the both groups, metformin and simvastatin administrated for eight weeks before starting the ICSI cycle. Endocrine, metabolic and clinical parameters were measured before and after drug therapy; also, the results of ICSI cycle evaluated in the both groups.Results:Both drugs improved hirsutism score significantly, but simvastatin better than metformin (Group A, 24.5 ± 3.6 P: 0.0001 VS Group B, 22.9 ± 5.9 P: 0.003). The reduction in body mass index (BMI) was not significant in the groups. Simvastatin reduced some biochemical parameters such as FSH, LH, testosterone, total cholesterol, LDL and increased HDL level significantly, whereas metformin decreased FSH, TG, testosterone and total cholesterol significantly. Overall, respectively 35% and 30% of patients treated with metformin and Simvastatin became pregnant. There was no significant difference between the effects of these two drugs on ICSI cycle results like oocyte in meiosis2 (M2) phase (1.35 ± 1.6 vs. 2 ± 3.87, P value: 0.4) and the number of Grade A, embryo (1.2 ± 1.3 vs. 1.1 ± 1.4, P value: 0.7).Conclusions:Simvastatin effectively improved hyperandrogenism signs and symptoms in patients with PCO, but this effect as a pretreatment regiment was not more expressive than metformin in ICSI cycle outcome.

MiRNA-592 is downregulated and may target LHCGR in polycystic ovary syndrome patients

The polycystic ovary syndrome (PCOS) is an endocrine disorder mainly associated with infertility. Abnormal regulation of relevant genes is required for follicular development in PCOS. In the current study, the expression of serum miRNAs of PCOS patients was explored using miRNA array followed by qRT-PCR assays. The circulating level of miR-592 was significantly down-regulated in PCOS patients in comparison with healthy controls. Furthermore, we found that miR-592 was inversely correlated with the level of luteinizing hormone/chorionic gonadotropin receptor (LHCGR). Computational analysis predicted that miR-592 interacts with the LHCGR mRNA via binding to a site located in the 3′UTR region. Using a luciferase-based reporter assay we found that miR-592 directly targeted the LHCGR. In KGN cell line, miR-592 overexpression inhibited cell viability and the transition of phase G1 to phase S. Knocking down of LHCGR inhibited cell viability and cell cycle progression in KGN cells, and LHCGR co-transfection reversed the inhibitory effect of miR-592. These results shed new light on the diagnosis and treatment of PCOS syndrome.

The association between Polycystic Ovary Syndrome (PCOS) and metabolic syndrome: a statistical modelling approach.

Polycystic ovary syndrome (PCOS) affects 12-21% of women. Women with PCOS exhibit clustering of metabolic features. We applied rigorous statistical methods to further understand the interplay between PCOS and metabolic features including insulin resistance, obesity and androgen status. Retrospective cross-sectional analysis. Women with PCOS attending reproductive endocrine clinics in South Australia for the treatment of PCOS (n = 172). Women without PCOS (controls) in the same Australian region (n = 335) from the Australian Diabetes, Obesity and Lifestyle Study (AusDiab), a national population-based study (age- and BMI-matched within one standard deviation of the PCOS cohort). The factor structure for metabolic syndrome for women with PCOS and control groups was examined, specifically, the contribution of individual factors to metabolic syndrome and the association of hyperandrogenism with other metabolic factors. Women with PCOS demonstrated clustering of metabolic features that was not observed in the control group. Metabolic syndrome in the PCOS cohort was strongly represented by obesity (standardized factor loading = 0·95, P < 0·001) and insulin resistance factors (loading = 0·92, P < 0·001) and moderately by blood pressure (loading = 0·62, P < 0·001) and lipid factors (loading = 0·67, P = 0·002). On further analysis, the insulin resistance factor strongly correlated with the obesity (r = 0·70, P < 0·001) and lipid factors (r = 0·68, P < 0·001) and moderately with the blood pressure factor (loading = 0·43, P = 0·002). The hyperandrogenism factor was moderately correlated with the insulin resistance factor (r = 0·38, P < 0·003), but did not correlate with any other metabolic factors. PCOS women are more likely to display metabolic clustering in comparison with age- and BMI-matched control women. Obesity and insulin resistance, but not androgens, are independently and most strongly associated with metabolic syndrome in PCOS.

Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria

What is the prevalence, phenotype and metabolic features of polycystic ovary syndrome (PCOS) in the same population according to three different diagnostic criteria? The prevalence of PCOS under National Institutes of Health (NIH), Rotterdam and Androgen Excess and PCOS (AE-PCOS) Society criteria was 6.1, 19.9 and 15.3%, respectively. PCOS carried a 2-fold increased risk of metabolic syndrome regardless of the diagnostic criteria used. The prevalence rates of PCOS differ depending on the diagnostic criteria used to define the syndrome. The current paper gives the prevalence rates of the component and composite phenotypes of PCOS in the same population and reports similar rates of metabolic syndrome in women with PCOS under contrasting diagnostic criteria. In this cross-sectional study, 392 women between the ages of 18 and 45 years were analyzed. When the prevalence of PCOS according to NIH was set to 8% with a precision of 2.2% and confidence interval of 95%, the sample size required for a prevalence survey was found to be 400 subjects. The study was carried out in the General Directorate of Mineral Research and Exploration, a government-based institute, in which the largest number of female staff (n = 527) are employed within a single institute in Ankara, Turkey. The study was performed between 7 December 2009 and 30 April 2010. All female subjects between the ages of 18 and 45 years were invited to participate. Women older than 45 or younger than 18 years, post-menopausal women, women with a history of hysterectomy or bilateral oopherectomy and pregnant women were excluded. Totally, 392 of the employees were recruited for the final analyses. The prevalence of PCOS under NIH, Rotterdam and AE-PCOS Society criteria were 6.1, 19.9 and 15.3%, respectively. While the prevalence of metabolic syndrome was 6.1% in the whole study group, within the patients diagnosed as PCOS according to NIH, Rotterdam and AE-PCOS Society criteria, it was 12.5, 10.3 and 10.0%, respectively. Even though we have included women working at a single institution with a high response rate for the participation, we cannot exclude potential selection bias due to undetermined differences between our sample and background community. We might have underestimated actual prevalence of metabolic syndrome in PCOS due to lack of oral glucose tolerance test 2 h glucose data. Current results can be generalized to Caucasian populations and may present variations in other populations according to race and ethnicity. This work was, in part, sponsored by Merck Serono. Not applicable.